Heparin-induced thrombocytopenia epidemiology and demographics: Difference between revisions
Rim Halaby (talk | contribs) m (Changed protection level for "Heparin-induced thrombocytopenia epidemiology and demographics" ([Edit=Allow only autoconfirmed users] (expires 14:29, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:29, 7 January 2014 (UTC)))) |
mNo edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | ||
==Overview== | ==Overview== | ||
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of [[Heparin-induced thrombocytopenia]] increases risks for other future thrombo-embolic events. | [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of [[Heparin-induced thrombocytopenia]] increases risks for other future thrombo-embolic events. | ||
Line 25: | Line 27: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WS}} | |||
{{WH}} |
Revision as of 19:41, 17 June 2016
Heparin-induced thrombocytopenia |
Differentiating Heparin-induced thrombocytopenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Heparin-induced thrombocytopenia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics |
FDA on Heparin-induced thrombocytopenia epidemiology and demographics |
CDC on Heparin-induced thrombocytopenia epidemiology and demographics |
Heparin-induced thrombocytopenia epidemiology and demographics in the news |
Blogs on Heparin-induced thrombocytopenia epidemiology and demographics |
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of Heparin-induced thrombocytopenia increases risks for other future thrombo-embolic events.
Epidemiology and demographics
Mortality
- Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
- Mortality rate can be as high as 20%
- 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)
United States of America
- Incidence varies from 1-5%.
Race
Some studies have shown that the incidences of heparin-induced thrombocytopenia (HIT) are commoner among white patients compared to non-white patients.
Sex
Female have increased risks compared to male for heparin-induced thrombocytopenia
Age
Risks for development of HIT Increases with age (>60years)